More recently, in vitro findings supported an anti-tumor activity and prolonged survival for IL-7-expressing AXL-CAR-T cells in a TNBC subcutaneous xenograft model (101), indicating the importance of AXL as a novel CAR-T cell therapy target in TNBC and its potential to modulate the TME to a proinflammatory state for effective anti-tumor immune responses. Here, IL7 is linked to neoplasm.